Abstract
Biotechnology's overall failure to achieve pharma's FIPCO model will, paradoxically, finally drive the industry to profitability.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scarlett, J. Biotechnology's emerging opportunities: Lessons from the Bauhaus. Nat Biotechnol 17 (Suppl 1), BE13–BE15 (1999). https://doi.org/10.1038/4629
Issue Date:
DOI: https://doi.org/10.1038/4629